摘要
目的探讨促红细胞生成素联合蔗糖铁治疗肾性贫血的临床疗效。方法选取2016年1月至2107年1月我院收治的肾性贫血74例,按随机数字表法分为两组,对照组37例,采取促红细胞生成素(EPO)治疗,观察组37例,在对照组治疗基础上联合蔗糖铁注射液治疗,治疗4w为1个疗程,均治疗1个疗程后,测定两组治疗前后血红蛋白(Hb)、血细胞比容(HCT)、血清铁蛋白(SF)、转铁蛋白(TRF)水平变化,比较两组治疗效果,并比较两组用药安全性。结果观察组治疗后Hb、HCT、SF水平均高于对照组,TRF水平低于对照组(P<0.05);观察组总有效率高于对照组(P<0.05);且两组无明显不良反应发生。结论对肾性贫血患者采取促红素联合铁剂治疗的效果较好,且用药安全。
Objective To investigate the clinical efficacy of erythropoietin combined with iron on renal anemia. Methods 74 cases of kidney from January 2016 to January 2107 in our hospital were anemia, were randomly divided into two groups, 37 cases in the control group, take erythropoietin(EPO) treatment, 37 cases in the observation group in the control group based on the combined treatment of Iron Sucrose Injection, 4 W treatment for 1 courses of treatment, were treated for 1 after treatment, the determination of the two groups before and after treatment of hemoglobin(Hb), hematocrit(HCT), serum ferritin(SF), transferrin(TRF) levels, the treatment effects were compared between the two groups, and compare two groups of drug safety. Results After treatment, the levels of Hb, HCT and SF in the observation group were higher than those in the control group, and the level of TRF was lower than that of the control group(P<0.05). The total effective rate of the observation group was higher than that of the control group(P<0.05). Conclusion The use of erythropoietin combined with iron therapy has good treatment effect on patients with renal anemia, and drug safety.
出处
《智慧健康》
2017年第19期97-98,共2页
Smart Healthcare